The Effect of Allergen Immunotherapy on Exhaled Nitric Oxide in Adult Patients With Asthma and Allergic Rhinitis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01318954

Enrollment

Registered

2011-03-21

Start date

2008-01-31

Completion date

2011-06-30

Last updated

2015-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Asthma, Allergic Rhinitis

Brief summary

This study will evaluate whether exhaled nitric oxide levels are affected by allergen immunotherapy (allergy shots). The investigators' hypothesis is that successful allergen immunotherapy may be accompanied by decreased exhaled nitric oxide levels.

Interventions

BIOLOGICALAllergen immunotherapy

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Subjects over 18 years old with allergic asthma and/or allergic rhinitis who are beginning allergen desensitization

Exclusion criteria

* Smokers * Subjects of dimished capacity

Design outcomes

Primary

Measure	Time frame
Effect of allergen immunotherapy on exhaled nitric oxide	One year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026